Quantum Leap: Rivals eye full-scale quantum computer finish line before 2030
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
VISIONS OF 2030: After a series of recent technical breakthroughs, the creation of full-scale quantum computers may be possible by the end of the decade, Richard Waters of The Financial Times reported. Back in June, IBM (IBM) became the latest to claim its path was clear to a full-scale machine, believing it could build the machine by the end of the decade. This has intensified its race with Google (GOOGL), which announced last year it cleared on of its largest remaining hurdles on creating one and said it was on course to finish by the end of the decade.
QUBITS JAPAN: D-Wave Quantum (QBTS) announced that it is hosting its first-ever Qubits Japan 2025 quantum computing user conference in Tokyo on September 17. Themed 'Quantum Realized,' Qubits Japan 2025 will feature presentations from D-Wave executives, customers, and thought leaders. The event comes as D-Wave's bookings in the APAC region are up 83% over the past 12 months.
CFO TRANSITION: FormFactor (FORM) announced that Aric McKinnis, currently its VP and corporate controller, has been appointed to serve as the company's new senior VP and CFO. He succeeds Shai Shahar, who resigned from these positions effective August 8. Shahar will remain a FormFactor employee as senior VP, executive advisor through December 31.
R&D HUB: Sealsq (LAES) unveiled the progress of its SEALQuantum.com Lab, a next-generation research and development hub focused on the convergence of quantum computing, and cybersecurity now expanding into artificial intelligence. With a total of $30M investment capacity, the Lab has already invested in quantum technology startups like ColibriTD and made the acquisition of semiconductor design service specialist IC'ALPS to develop solutions for semiconductor manufacturing and post-quantum security.
SCALEUP X: Arqit Quantum (ARQQ) announced that it has joined the 2025 cohort of Tomorrow Street's Scaleup X program. The collaboration provides Arqit with access to Tomorrow Street's global network and ecosystem, creating opportunities to scale its technology across Vodafone's (VOD) ecosystem. Andy Leaver, CEO of Arqit, commented: 'We are thrilled to join Tomorrow Street's Scaleup X Programme. In the International Year of Quantum Science and Technology, there's global recognition of the urgent need to adopt quantum-safe encryption solutions. The ability to engage with Tomorrow Street's ecosystem provides a major opportunity to accelerate commercial deployments and deliver next-generation cyber security to customers across telecoms, critical infrastructure and enterprise sectors.'
NEW CHAIR: IonQ 's (IONQ) board of directors has appointed CEO Niccolo de Masi to the additional position of chairman of the board, effective immediately. As a result, Peter Chapman has stepped down as executive chairman and as a member of the board.
EARNINGS RECAP: Shares of Rigetti Computing (RGTI) dipped 3% after the company's Q2 results fell shy of expectations. Net loss in the quarter included $22.8M of non-cash losses for the fair value change in the derivative warrant and earn-out liabilities. 'It's our view that superconducting qubits are the leading modality for quantum computers due to their ability to scale, and their ability to achieve gate speeds more than 1,000 times faster than other modalities like ion traps and pure atoms. Rigetti's superconducting qubits leverage technologies, like chiplets, that have been maturing in the semiconductor industry for decades, enabling Rigetti to use well-established methods to scale to higher performance and qubit counts,' CEO Subodh Kulkarni commented.
D-Wave reported mixed Q2 results, beating revenue expectations, but missing the EPS mark compared with analyst consensus. Bookings for the second quarter were $1.3M. 'Our second quarter results show consistently strong performance across a multitude of technical and business metrics,' said Alan Baratz, CEO of D-Wave. 'During the quarter, we brought to market our sixth-generation quantum computer, signed a memorandum of understanding related to the acquisition of an on-premises system in South Korea, completed physical assembly of the previously announced system at Davidson Technologies, introduced a collection of developer tools to advance quantum AI and machine learning innovation, and ended the quarter with a record $819 million in cash. We're confident in our ability to continue delivering long-term value for our customers, partners and shareholders.' Piper Sandler raised the firm's price target on D-Wave Quantum to $22 from $13 and maintained an Overweight rating on the shares. The firm notes the company reported June earnings in which revenue was slightly above expectations into the print. The company is currently benefiting from the availability of its Advantage2 system and general quantum computing traction which came online in the June quarter, the firm told investors in a research note.
Similarly, IonQ also experienced a mixed second quarter. Cash, cash equivalents, and investments were $656.8M as of June 30 and $1.6B pro-forma as of July 9. The balance increased due to the $1B equity financing. CEO Niccolo de Masi said, 'I am pleased to report that we beat the top end of guidance for Q2 revenue by 15%, and strengthened our balance sheet via the largest equity investment from a single institution in the quantum industry. We also made very tangible progress towards delivering our #AQ64 application performance benchmark, with strong indications that it will be achieved in the near term.'
ADDITIONAL ANALYST COMMENTARY: DA Davidson downgraded IonQ to Neutral from Buy with an unchanged price target of $35. IonQ continues to invest heavily for what the firm believes will be 'the next big technological paradigm of this generation,' but risks associated with the business have notably increased given limited clarity relating to the roadmap and near-to-medium term profitability, said the analyst, who is moving to the sidelines based on 'various moving pieces and limited visibility.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Jim Cramer on International Business Machines: 'I Think They Have the Lead in Quantum'
International Business Machines Corporation (NYSE:IBM) is one of the stocks Jim Cramer shed light on. A caller asked for Cramer's thoughts on the company, and he remarked: 'Okay, I didn't think IBM's quarter… was all that bad at all. I think you have a major opportunity down here because I think that we're going to start talking about IBM and quantum. I think they have the lead in quantum, and I think quantum really does matter. They have a great software package. They're doing so many things that are good. Tauke / International Business Machines Corporation (NYSE:IBM) provides integrated solutions across software, consulting, infrastructure, and financing. The company offers hybrid cloud and AI platforms, technology services, and IT financing solutions. While we acknowledge the potential of IBM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
6 hours ago
- Yahoo
Merck KGaA ventures into new territory in the US
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck KGaA has been making new moves to propel itself into becoming what CEO Belén Garijo described as a 'globally diversified science and technology powerhouse.' Most recently, the company closed its $3.4 billion acquisition of Pfizer spinout SpringWorks Therapeutics, which will help it stake a claim in the rare tumor space. And in general, it's all about 'doubling down' on R&D and building the company's U.S. footprint, said Miguel Fernández Alcalde, president of EMD Serono, Merck KGaA's healthcare business in the U.S. and Canada. Germany-based Merck KGaA has undergone a number of transformations throughout its deep history. In 2022, the company restructured into three distinct business units including one focused on the life sciences sector and manufacturing services. But with the contract manufacturing blitz of the COVID-19 pandemic era fading, the company is refocusing. EMD Serono relocated its U.S. headquarters to Boston's Seaport district to place itself squarely in the thick of the region's most innovative 'biotechs, startups, academia and scientists,' Fernández Alcalde said. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization." Miguel Fernández Alcalde President, EMD Serono Merck KGaA also elevated its global head of R&D and chief medical officer of its healthcare business, Dr. Danny Bar-Zohar, to healthcare CEO. 'That tells you that the company's moving along in the direction of doubling down on R&D,' Fernández Alcalde said. Fernández Alcalde's appointment to president of EMD Serono in December is also part of the company's overall quest to build its U.S. footprint and bolster R&D through external deals. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization,' he said. 'I do think we have lots of opportunities in the U.S. ecosystem and U.S. market. My job and my vision and ambition is to really untap all those things that we have ahead of us.' A pharmacist by trade, Fernández Alcalde has been with Merck KGaA since 2014, serving most recently as EMD Serono's chief operating officer. 'That gave me a lot of knowledge and understanding of the business of the company in the States and the teams, the dynamics, the culture, but also the U.S. [healthcare] ecosystem,' he said. Driving dealmaking Central to Fernández Alcalde's role is supplementing the company's current pipeline through external innovation investments, including more strategic in-licensing and co-development opportunities. The SpringWorks acquisition put the company on track to generate at least 50% of its future launch assets from external companies, compared to roughly 10%-15% just 18 months ago. 'It's easily a fivefold increase in our ambition from external innovation,' Fernández Alcalde said. In terms of what kinds of deals they're targeting, Fernández Alcalde said several factors are at play. 'We are not looking [for] the $40 billion type of acquisition,' he said. Nor will they chase first-in-class potential blockbusters with never-explored mechanisms of action. Instead, they'll target smaller deals with the 'right risk balance' for their pipeline. He pointed to the SpringWorks acquisition as an example, which not only adds two FDA-approved drugs to its portfolio, but also a 'runway of three to five years of nice growth' in the form of several clinical-phase pipeline candidates. 'These areas where we have deep, good science [and a] validated proof of concept or an about-to-be-validated proof of concept where the mechanism of action is already validated, is something we are interested in,' he said. The company will take a similar approach when it comes to therapeutic areas by branching out within reason. 'We are not sticking to the [therapeutic areas] we have today, but we are not going to go wild, either,' he said. Rather, they'll look for specialties that are 'adjacent' and 'logical' in terms of what they've been historically known for, such as oncology and neurology/immunology. Again, he pointed to the SpringWorks acquisition as an example and noted that some might ask what track record EMD Serono or Merck KGaA has in rare tumors. 'The answer is zero. But we do know how to commercialize,' he said. Plus, 'it's in an adjacent area of oncology.' Fernández Alcalde is also thinking globally, intending to follow good science wherever it leads and consider deals from around the world. 'We couldn't care less about where that science is coming from, whether it's China, my home country Spain, the U.S. or South Africa,' he said. 'If we think that science will help patients … we will definitely think about it.' Recommended Reading Let's make a deal? Big Pharma execs express varying views on their M&A future
Yahoo
7 hours ago
- Yahoo
Quantum Stocks Q2 2025: Are D-Wave, IonQ & Rigetti Funding the Future?
As second-quarter 2025 earnings rolled in, three pure-play quantum computing companies, D-Wave Quantum QBTS, Rigetti Computing RGTI and IonQ IONQ, offered a snapshot of an industry that moves at light speed but still sees profitability as a distant horizon. The trio's results revealed a common storyline, strong sales, bigger losses and huge cash reserves to fund the next big step in quantum computing. D-Wave D-Wave Quantum's second-quarter 2025 revenues rose 42% year over year, driven by Advantage2 quantum processing unit sales, including the system installed at Julich Supercomputing Center earlier this year. The company expanded its customer base with contracts from GE Vernova, Nikon and NTT DOCOMO, and strengthened global ties through partnerships in South Korea. Technological progress included an open-source PyTorch toolkit and quantum-assisted image generation demos. Collaborating with NASA's Jet Propulsion Laboratory on advanced cryogenic packaging, D-Wave aims to accelerate its push toward a 100,000-qubit system, reinforcing its leadership in annealing quantum computing while broadening its international footprint. Financially, the company ended the quarter with a record $819.3 million in cash—an over 1,900% year-over-year increase driven by a $400 million at-the-market equity raise, warrant exercises and credit facility proceeds. Gross profit grew 42%, while adjusted EBITDA loss widened 44% year over year due to higher operating expenses from aggressive R&D and market expansion efforts. With strong liquidity, an expanding enterprise pipeline and parallel development in both annealing and gate-model architectures, D-Wave signaled that it is prepared to invest heavily in scaling technology and pursuing strategic acquisitions, while maintaining its ambition to be the first independent public quantum computing firm to achieve sustained profitability. IonQ IonQ delivered a standout second-quarter 2025, with revenues coming in 15% above the top end of guidance, reflecting accelerating commercial traction across quantum computing and networking. The company's momentum was underpinned by high-profile partnerships, including a landmark $22 million deal to build America's first commercial quantum hub with utility leader EPB, and a 20x performance speed-up in quantum-accelerated drug development alongside AstraZeneca AZN, AWS and NVIDIA NVDA. However, the aggressive push into R&D, strategic acquisitions and talent expansion incurred steep costs. IonQ reported a net loss of $177.5 million and an adjusted EBITDA loss of $36.5 million for the quarter. Despite being in the red, IonQ now commands one of the strongest balance sheets in the quantum sector, closing a $1 billion equity investment, priced at a premium that boosted its pro forma cash position to $1.6 billion as of July 2025. This war chest gives the company ample runway to execute on its roadmap, including integrating Oxford Ionics' ion-trap-on-a-chip technology and scaling toward 800 logical qubits by 2027 and 80,000 by 2030. With acquisitions like Lightsynq and Capella expanding its reach into photonic interconnects and space-based quantum key distribution, IonQ is positioning itself to lead the next leap in computing power while fortifying its role in the future quantum Internet. Rigetti Rigetti Computing's second-quarter 2025 revenues reflected sequential growth but declined year over year due to the expiration of the U.S. National Quantum Initiative and delays in its reauthorization. Gross margin narrowed to 31% from 64% a year earlier, primarily due to revenue mix and lower-margin development contracts. The company incurred an operating loss and a net loss in the quarter, the latter impacted by non-cash losses tied to changes in derivative warrant and earn-out liabilities. Management reiterated that hitting technology milestones remains central to its long-term profitability path, with Quantum Advantage targeted in roughly four years through scaling qubit counts, improving gate fidelity and advancing error correction. On a positive note, the company's balance sheet is notably fortified, following the completion of a $350 million equity raise during the quarter, bringing total cash, cash equivalents and available-for-sale investments to $571.6 million as of June 30, 2025, with no debt. This sizable war chest provides ample runway to fund R&D, scale commercial operations and potentially pursue strategic collaborations or acquisitions. Rigetti intends to leverage its proprietary chiplet-based superconducting qubit technology to reach a 100-plus qubit system with 99.5% median two-qubit gate fidelity by year-end 2025, an important step on the roadmap toward fault tolerance and eventual commercial-grade quantum computing profitability. Conclusion Taken together, revenues are rising and technology is advancing, but cash burn is heavy and profitability is far off for these three stocks. In this race, massive cash reserves are the fuel, and the first one to deliver scalable, commercially viable quantum systems will be the winner. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report IonQ, Inc. (IONQ) : Free Stock Analysis Report Rigetti Computing, Inc. (RGTI) : Free Stock Analysis Report D-Wave Quantum Inc. (QBTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
